Table 2 Effects on peripheral blood cytokines and angiogenic factors
Baseline | Month 3 | ||||
|---|---|---|---|---|---|
Cytokine and angiogenic factor treatment group | Median (pg ml−1) | IQR (pg ml−1) | Median (pg ml−1) | IQR (pg ml−1) | P -value a |
Hepatocyte growth factor (HGF) | |||||
Usual care | 226 | 132–354 | 295 | 218−503 | |
Aerobic training | 310 | 209–499 | 236 | 130–426 | 0.008 |
Interleukin-4 (IL-4) | |||||
Usual care | 117 | 77–122 | 120 | 79–138 | |
Aerobic training | 115 | 77–120 | 111 | 74–120 | 0.012 |
MIP-1 β/CCL4 | |||||
Usual care | 152 | 125–199 | 159 | 136−217 | |
Aerobic training | 177 | 123–265 | 163 | 114−205 | 0.034 |
Vascular endothelial growth factor (VEGF) | |||||
Usual care | 9 | 1–18 | 11 | 3−16 | |
Aerobic training | 13 | 3–22 | 10 | 1–20 | 0.043 |
Tumour necrosis factor- α (TNF- α) | |||||
Usual care | 2 | 1–3 | 3 | 1–5 | |
Aerobic training | 1 | 1–3 | 1 | 1–3 | 0.046 |